BioLife Solutions Inc (NASDAQ:BLFS) Director Johan Wedell-Wedellsborg sold 17,243 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $27.00, for a total transaction of $465,561.00.
Shares of NASDAQ BLFS traded up $0.32 during trading on Thursday, hitting $19.41. The stock had a trading volume of 5,152 shares, compared to its average volume of 172,177. BioLife Solutions Inc has a 12 month low of $9.15 and a 12 month high of $22.44. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.42 and a quick ratio of 7.71. The company has a market capitalization of $362.77 million, a PE ratio of 139.00 and a beta of 1.43. The firm has a fifty day moving average of $19.20 and a two-hundred day moving average of $17.94.
BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.65%. The firm had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.59 million. On average, equities analysts expect that BioLife Solutions Inc will post 0.08 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of BLFS. Park West Asset Management LLC grew its position in BioLife Solutions by 1,577.3% during the second quarter. Park West Asset Management LLC now owns 344,255 shares of the medical equipment provider’s stock valued at $5,835,000 after buying an additional 323,731 shares during the period. BlackRock Inc. lifted its holdings in BioLife Solutions by 129.3% during the second quarter. BlackRock Inc. now owns 541,305 shares of the medical equipment provider’s stock valued at $9,177,000 after purchasing an additional 305,276 shares during the last quarter. River & Mercantile Asset Management LLP purchased a new stake in BioLife Solutions during the second quarter valued at about $3,807,000. Russell Investments Group Ltd. lifted its holdings in BioLife Solutions by 230.8% during the second quarter. Russell Investments Group Ltd. now owns 299,240 shares of the medical equipment provider’s stock valued at $5,067,000 after purchasing an additional 208,786 shares during the last quarter. Finally, FMR LLC purchased a new stake in BioLife Solutions during the first quarter valued at about $2,684,000. Hedge funds and other institutional investors own 48.44% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
See Also: What is the definition of market timing?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.